Bristol-Myers Squibb turns to an AI startup to accelerate cancer research
NewsMedia Coverage
The deal with ConcertAI, a Boston-based firm backed by the $1 billion SymphonyAI fund, is an effort to infuse real-world evidence from medical practices across the U.S. into Bristol’s research.